Ikena Oncology Inc (IKNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ikena Oncology Inc (IKNA) has a cash flow conversion efficiency ratio of -0.030x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.42 Million) by net assets ($115.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IKNA market cap for the company's overall valuation and market capitalisation.
Ikena Oncology Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Ikena Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ikena Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ikena Oncology Inc ranked by their cash flow conversion efficiency. Explore IKNA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cryomax Cooling System Corp
TW:1587
|
0.052x |
|
Tex-Ray Industrial Co Ltd
TW:1467
|
0.032x |
|
VITA 34 AG
XETRA:V3V
|
0.078x |
|
LLORENTE + CUENCA EO -01
F:91P
|
N/A |
|
Sow Good Inc. Common Stock
NASDAQ:SOWG
|
0.489x |
|
Citizens Holding Company
NASDAQ:CIZN
|
0.016x |
|
TEAM INC. DL-30
F:T9CA
|
-0.685x |
|
Kawan Food Bhd
KLSE:7216
|
-0.025x |
Annual Cash Flow Conversion Efficiency for Ikena Oncology Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Ikena Oncology Inc from 2018 to 2024. View Ikena Oncology Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $125.93 Million | $-46.00 Million | -0.365x | +22.23% |
| 2023-12-31 | $169.76 Million | $-79.74 Million | -0.470x | +6.84% |
| 2022-12-31 | $146.97 Million | $-74.11 Million | -0.504x | -73.97% |
| 2021-12-31 | $207.88 Million | $-60.25 Million | -0.290x | -177.43% |
| 2020-12-31 | $-101.05 Million | $-37.83 Million | 0.374x | +148.01% |
| 2019-12-31 | $-61.46 Million | $47.93 Million | -0.780x | -407.93% |
| 2018-12-31 | $-45.84 Million | $-11.61 Million | 0.253x | -- |
About Ikena Oncology Inc
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by… Read more